ChemoMetec A/S (FRA:CHY)

Market Cap	1.78B
Revenue (ttm)	66.43M
Net Income (ttm)	24.99M
Shares Out	n/a
EPS (ttm)	1.44
PE Ratio	71.23
Forward PE	53.48
Dividend	0.94 (0.89%)
Ex-Dividend Date	Oct 10, 2025

Volume	31
Average Volume	23
Open	103.90
Previous Close	103.10
Day's Range	103.90 - 105.50
52-Week Range	51.90 - 106.60
Beta	n/a
RSI	64.82
Earnings Date	Feb 4, 2026

About ChemoMetec

ChemoMetec A/S engages in the development, production, and sale of analytical equipment for cell counting and analysis the United States, Canada, Europe, and internationally. The company offers its solutions in the areas of cell and gene therapy, cancer and stem cell research, and development and manufacturing of pharmaceuticals, as well as production and quality control of animal semen, milk, and beer. Its products include NucleoCounter NC-3000, an advanced image cytometer; NucleoCounter NC-250, an automated cell analyzer; NucleoCounter NC-202...

• Industry: Electromedical and Electrotherapeutic Apparatus
• Founded: 1997
• Employees: 170
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: CHY

Financial Performance

In 2025, ChemoMetec's revenue was 495.57 million, an increase of 21.50% compared to the previous year's 407.87 million. Earnings were 186.41 million, an increase of 36.78%.

Financial numbers in DKK